Source link : https://www.newshealth.biz/health-news/radioligand-shows-promise-in-metastatic-hormone-sensitive-prostate-cancer/
In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more than doubled biochemical recurrence-free survival (BRFS), the randomized UpFrontPSMA trial showed. BRFS at 48 weeks, defined as a prostate-specific antigen (PSA) value ≤0.2 ng/mL, increased from 16% with ADT and docetaxel to 41% with the addition […]
Author : News Health
Publish date : 2024-10-16 21:42:34
Copyright for syndicated content belongs to the linked Source.